Investment case
Cigna Group
CI · 6 developments mapped · last assessed 2026-09-18
Market Ontology has mapped 6 macro, policy, and market developments to Cigna Group since 2026-09-18. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CI yet, so no modelled value is shown. The CI valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CI on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Increased prescription volume and formulary management fees for GLP-1 drugs through its PBM segment (Express Scripts).
· Moves pharmacy services revenue growth, pbm profitability
- Open question
Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
As a major PBM (Express Scripts), formulary access for new, high-cost drugs like Foundayo impacts drug spend, rebate negotiations, and potential for increased prescription volume.
· Moves pharmacy benefit management profitability, drug spend trends, rebate capture rates
What changed, by assumption
- 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
- 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-18 | Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary | Bullish | 1-3m | 0.60 |
| 2026-09-18 | Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage | Bullish | 3-12m | 0.60 |
| 2026-09-18 | Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs | Bullish | 1-3m | 0.60 |
| 2026-09-18 | Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands | Bullish | 3-12m | 0.60 |
| 2026-09-18 | Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands | watch | 1-3m | 0.50 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage | Bullish | 1-3m | 0.60 |